Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "UK"

825 News Found

ANVISA inspection received from Brazil Health Regulatory Agency at Wanbury Tanuku facility
Drug Approval | December 21, 2024

ANVISA inspection received from Brazil Health Regulatory Agency at Wanbury Tanuku facility

The company will receive GMP compliance certificate which will further help to accelerate the business growth across the globe


Bayer announces positive topline resukts for Aflibercept 8 mg in phase III study
Diagnostic Center | December 17, 2024

Bayer announces positive topline resukts for Aflibercept 8 mg in phase III study

Demonstrates vision gains with extended treatment intervals in retinal vein occlusion


Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, and Japan
News | August 30, 2024

Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, and Japan

Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025


UK Relonchem receives marketing authorization for Levonorgestrel 1.5 mg Tablets
News | August 06, 2024

UK Relonchem receives marketing authorization for Levonorgestrel 1.5 mg Tablets

Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA


Aurobindo Pharma’s subsidiary acquires Ace Laboratories, UK
News | June 29, 2024

Aurobindo Pharma’s subsidiary acquires Ace Laboratories, UK

Ace Lab conducts 170 batches of testing per month and has capacity to do more than 250 batches per month


Asymchem acquires former Pfizer small molecule API pilot plant in Sandwich, UK
News | May 23, 2024

Asymchem acquires former Pfizer small molecule API pilot plant in Sandwich, UK

Establishing Asymchem’s first manufacturing footprint in Europe


Sentynl Therapeutics receives marketing authorization for Nulibry from UK MHRA
Drug Approval | April 22, 2024

Sentynl Therapeutics receives marketing authorization for Nulibry from UK MHRA

NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A


Pfizer’s Velsipity UK approval will raise competition in ulcerative colitis market, says GlobalData
Drug Approval | April 06, 2024

Pfizer’s Velsipity UK approval will raise competition in ulcerative colitis market, says GlobalData

The approval marks a significant milestone for the American pharmaceutical company in the field of UC


Biocon's European partner Zentiva receives approval from UK MHRA for Liraglutide
Drug Approval | April 01, 2024

Biocon's European partner Zentiva receives approval from UK MHRA for Liraglutide

The company had earlier announced about the approval received from the MHRA for Liraglutide